Skip to main content

Advertisement

Table 5. Completed clinical trials of Akt inhibitors in OC

From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

Phase Treatment No. of OC patients Selected toxicities Efficacy Reference
I Perifosine (MTD = 150 mg/day) + docetaxel 21 Nausea, vomiting, anorexia, and fatigue At MTD in 11 patients, PR in 1 PTEN-null patient, SD in 3 patients Fu et al.[37]
I GSK795 (25, 50, or 75 mg/day) 12 Grade 2 anorexia (18%) and vomiting (18%) 2 (16%) cases of SD for 6 months with tumor shrinkage of 26% and 11%, respectively Gungor et al.[38]
I GSK211 (50–150 mg/day) + carboplatin (AUC = 5) + paclitaxel (175 mg/m2) 29 Grade 1/2 diarrhea, nausea, and fatigue All patients in dose escalation: ORR = 30%; At MTD: ORR = 50% Blagden et al.[39]
At MTD: ORR = 50%
  1. MTD, maximal tolerated dose; AUC, area under curve; SD, stable disease; ORR, objective response rate.